The fixed-dose combination of brinzolamide 1% and brimonidine 0.2% (BBFC) is superior to vehicle in lowering intraocular pressure (IOP) over a 24-hour period following 4 weeks of 3-times-daily treatment in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), a study has shown.
A novel incentive strategy which rewards patients who are compliant to their medications significantly improves adherence rates, thus providing a potential cost-effective adherence intervention, the SIGMA* study shows.
Normal-tension glaucoma patients with low night-time through diastolic blood pressure (DBP) are at heightened risk of visual field progression, and this risk is associated with the duration and magnitude of nocturnal DBP dip, a study has found.
Greater physical activity, such as increased walking and more time spent doing moderate-to-vigorous or nonsedentary activity, may reduce visual field (VF) loss in a treated population of patients with glaucoma, a study has found. Moreover, adding 5,000 daily steps or 2.6 hours of nonsedentary physical activity decreases the average rate of VF by 10 percent.
Use of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular oedema (DME) in routine clinical practice does not escalate the hazard of cerebrovascular disease, myocardial infarction or major bleeding within 6 months after treatment, reports a study.
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).